Next Article in Journal
Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine
Previous Article in Journal
Impact of Chromosomal Rearrangements on the Interpretation of Lupin Karyotype Evolution
Previous Article in Special Issue
Epidemiology of Hepatitis B Virus Infection in Bangladesh: Prevalence among General Population, Risk Groups and Genotype Distribution
Article Menu

Export Article

Open AccessReview
Genes 2019, 10(4), 260; https://doi.org/10.3390/genes10040260

Meeting the Challenge of Eliminating Chronic Hepatitis B Infection

1
Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia
2
Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia
3
Directorate, Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia
4
University of South Florida, Tampa, FL 33612, USA
5
Romark Laboratory, Tampa, FL 33607, USA
6
Global Virus Network, Baltimore, MD 21201-1009, USA
7
INSERM Unit 1052—Cancer Research Center of Lyon, 69000 Lyon, France
*
Author to whom correspondence should be addressed.
Received: 14 December 2018 / Revised: 29 January 2019 / Accepted: 1 February 2019 / Published: 1 April 2019
PDF [485 KB, uploaded 18 April 2019]
  |  

Abstract

Over 257 million people live with chronic hepatitis B virus (HBV) infection and there is no known cure. The effective preventative vaccine has no impact on existing infection. Despite the existence of drugs which efficiently suppress viral replication, treatment is usually life-long and finite therapies that cure HBV infection are urgently required. However, even if such therapies were available today, it is unlikely they would reach all of those who need it most, due to chronic hepatitis B (CHB) being largely undiagnosed across the globe and to the dire need for health systems promoting access to therapy. Considerable challenges to developing and implementing an effective HBV cure remain. Nonetheless, important advances towards a cure are being made, both in the development of a multitude of new therapeutic agents currently undergoing clinical trials, and through the establishment of a new global initiative dedicated to an HBV cure, ICE-HBV, that is working together with existing organisations to fast-track an HBV cure available to all.
Keywords: ICE-HBV; chronic HBV disease; persistence; HBV cure; treatment; current clinical trials ICE-HBV; chronic HBV disease; persistence; HBV cure; treatment; current clinical trials
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Revill, P.A.; Penicaud, C.; Brechot, C.; Zoulim, F. Meeting the Challenge of Eliminating Chronic Hepatitis B Infection. Genes 2019, 10, 260.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Genes EISSN 2073-4425 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top